Valuation : CS Diagnostics Corp.

Market Cap 7.25M 6.24M 5.87M 5.35M 10.01M 690M 10.05M 69.62M 26.91M 351M 27.22M 26.63M 1.11B P/E 2024
232,000x
P/E 2025 1,077x
Enterprise Value 7.24M 6.23M 5.87M 5.35M 10M 689M 10.04M 69.55M 26.88M 351M 27.2M 26.61M 1.11B EV / Sales 2024
1,357x
EV / Sales 2025 375x
Free-Float
14.55%
Yield 2024 *
-
Yield 2025 -
1 day+163.64%
Current month+176.19%
1 month-58.57%
3 months-55.38%
6 months-80.67%
Current year-90.52%
1 month 0.01
Extreme 0.0085
0.03
Current year 0.01
Extreme 0.0085
0.4
1 year 0.01
Extreme 0.0085
0.4
3 years 0.01
Extreme 0.0085
5.64
5 years 0.01
Extreme 0.0085
8.5
10 years 0.01
Extreme 0.0085
28.95
Manager TitleAgeSince
Chief Executive Officer 56 2022-03-31
Director of Finance/CFO 47 2021-12-31
Corporate Officer/Principal 45 2024-07-17
Director TitleAgeSince
Chairman 56 1996-09-24
Director/Board Member 47 2021-12-31
Director/Board Member 54 2025-08-31
Date Insider Type Main position Quantity % Market Cap. Importance
12/31/25 Other

Chief Executive Officer

49,362,500 35.9418%
12/31/25 Other

Chief Executive Officer

104,507,800 76.0941%
12/31/25 Other

Chief Executive Officer

42,560,096 30.9888%
Change 5-day change 1-year change 3-year change Capi.($)
+163.64%0.00%-84.74%-73.64% 7.25M
-0.27%-4.74%-20.25%+4.47% 182B
-0.54%-0.31%-2.32%+14.92% 118B
-0.42%-3.88%+8.25%+81.95% 61.7B
-0.73%-5.83%+11.17%+43.25% 50.55B
+0.98%-4.12%-5.61%-32.60% 48.98B
-0.77%-6.48%+6.99%-19.62% 31.65B
-1.84%-6.20% - - 29.87B
-0.24%-1.66%+33.69%-14.30% 23.71B
-2.25%-10.09%-14.34%+3.57% 21.78B
Average +15.76%-3.62%-7.46%+0.89% 56.79B
Weighted average by Cap. -0.46%-3.00%-4.56%+13.63%

Financials

2024 2025
Net sales 111K 95.44K 89.86K 81.88K 153K 10.55M 154K 1.07M 412K 5.38M 416K 407K 17.03M 204K 176K 165K 151K 282K 19.41M 283K 1.96M 757K 9.89M 766K 749K 31.33M
Net income 761 654.84 616.59 561.82 1.05K 72.41K 1.06K 7.31K 2.82K 36.89K 2.86K 2.8K 117K 71.22K 61.28K 57.7K 52.58K 98.37K 6.78M 98.77K 684K 264K 3.45M 267K 262K 10.94M
Net Debt -501 -431.11 -405.93 -369.87 -692.03 -47.67K -694.79 -4.81K -1.86K -24.29K -1.88K -1.84K -76.94K -6.81K -5.86K -5.52K -5.03K -9.41K -648K -9.45K -65.42K -25.29K -330K -25.58K -25.03K -1.05M
Logo CS Diagnostics Corp.
CS Diagnostics Corp is a Germany-based medical technology and distribution company. The Company is focused on developing and commercializing therapeutic and preventive solutions to improve patient care and outcomes. Its primary products are CS Protect-Hydrogel, a tissue spacer gel designed for use in radiation therapy, and MEDUSA, a surface disinfectant. CS Protect Hydrogel is an injectable organ spacer initially targeted for prostate cancer radiotherapy, where it increases the distance between the prostate tumor and the rectum to reduce radiation damage to healthy tissue. It is ready-to-use (pre-mixed in a sterile package) rather than requiring on-site mixing by clinicians. MEDUSA’s formulation provides an extended duration of antimicrobial protection on surfaces. It includes color-changing test strips that allow users to verify the concentration of the active ingredient over time.
Employees
1
Date Price Change Volume
26-09-02 US$0.0290 +163.64% 11,620
  1. Stock Market
  2. Stocks
  3. CSDX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!